Skip to main content

CIMZIA® (certolizumab pegol)

Legal Disclaimer

Read important information related to your request

The material below is provided in response to your specific search for information on UCBCOMPASS® IMMUNOLOGY and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. See FDA-approved indications  .

CIMZIA® is associated with a BOXED WARNING regarding serious infections and malignancy and important WARNINGS AND PRECAUTIONS, including heart failure, anaphylaxis or serious allergic reactions, hepatitis B virus reactivation, demyelinating disease, cytopenias or pancytopenia, and Lupus-like syndrome.

Please review the Full Prescribing Information here.

This material is not for distribution or reproduction.

FDA Approved Indications

CIMZIA® is a tumor necrosis factor (TNF) blocker indicated for:

  • Reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
  • Treatment of adults with moderately to severely active rheumatoid arthritis
  • Treatment of adult patients with active psoriatic arthritis
  • Treatment of adults with active ankylosing spondylitis
  • Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation
  • Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy